These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22959034)

  • 1. Targeted therapy for gastric adenocarcinoma.
    Almhanna K
    Adv Pharmacol; 2012; 65():437-70. PubMed ID: 22959034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of advanced gastric cancer.
    Price TJ; Shapiro JD; Segelov E; Karapetis CS; Pavlakis N; Van Cutsem E; Shah MA; Kang YK; Tebbutt NC
    Expert Rev Gastroenterol Hepatol; 2012 Apr; 6(2):199-208; quiz 209. PubMed ID: 22375525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
    Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
    Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy for advanced esophagogastric adenocarcinoma.
    Kordes S; Cats A; Meijer SL; van Laarhoven HW
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):68-76. PubMed ID: 24183912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review.
    Kuo HY; Yeh KH
    Anticancer Res; 2014 Jul; 34(7):3695-9. PubMed ID: 24982389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
    Kaur A; Dasanu CA
    Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies in the treatment of gastric cancer.
    Ngeow J; Tan IB; Choo SP
    Asia Pac J Clin Oncol; 2011 Sep; 7(3):224-35. PubMed ID: 21884434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances and future trends in the targeted therapy of metastatic gastric cancer.
    Al-Batran SE; Werner D
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):555-69. PubMed ID: 24665840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of chemotherapy in metastatic gastric cancer.
    Pasini F; Fraccon AP; DE Manzoni G
    Anticancer Res; 2011 Oct; 31(10):3543-54. PubMed ID: 21965776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
    Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
    Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel targets in gastric and esophageal cancer.
    Valverde CM; Macarulla T; Casado E; Ramos FJ; Martinelli E; Tabernero J
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):128-38. PubMed ID: 16829119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies in gastroesophageal cancer.
    Kasper S; Schuler M
    Eur J Cancer; 2014 May; 50(7):1247-58. PubMed ID: 24495747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer.
    Inui T; Asakawa A; Morita Y; Mizuno S; Natori T; Kawaguchi A; Murakami M; Hishikawa Y; Inui A
    J Intern Med; 2006 Nov; 260(5):484-7. PubMed ID: 17040255
    [No Abstract]   [Full Text] [Related]  

  • 14. Gastric Carcinoma at the Era of Targeted Therapies.
    Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
    Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?
    Pasini F; Fraccon AP; Modena Y; Bencivenga M; Giacopuzzi S; La Russa F; Gusella M; de Manzoni G
    Gastric Cancer; 2017 Jan; 20(1):31-42. PubMed ID: 27568322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
    Ajani JA; Lee FC; Singh DA; Haller DG; Lenz HJ; Benson AB; Yanagihara R; Phan AT; Yao JC; Strumberg D
    J Clin Oncol; 2006 Feb; 24(4):663-7. PubMed ID: 16446338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
    Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Met targeting in advanced gastric cancer: An open challenge.
    Marano L; Chiari R; Fabozzi A; De Vita F; Boccardi V; Roviello G; Petrioli R; Marrelli D; Roviello F; Patriti A
    Cancer Lett; 2015 Aug; 365(1):30-6. PubMed ID: 26049023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel targets in esophageal and gastric cancer: beyond antiangiogenesis.
    Lee W; Patel JH; Lockhart AC
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1351-64. PubMed ID: 19642951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment.
    Maresch J; Schoppmann SF; Thallinger CM; Zielinski CC; Hejna M
    Crit Rev Oncol Hematol; 2012 Jun; 82(3):310-22. PubMed ID: 21783379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.